A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy
Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes the activity of APRIL. It should usher in a new era in the treatment of IgAN, especially in elderly patients.
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wiley
2025-02-01
|
| Serija: | Aging Medicine |
| Teme: | |
| Online dostop: | https://doi.org/10.1002/agm2.12370 |
| Oznake: |
Brez oznak, prvi označite!
|